The invention concerns a novel viral vector with modified viral capsid or viral envelope; a pharmaceutical composition or immunogenic agent or vaccine comprising same; a target cell transformed or transfected with same; a combination therapeutic comprising same; use of same in treatment of cancer, and a method of treating cancer using same.

The invention concerns a novel viral vector with modified viral capsid or viral envelope; a pharmaceutical composition or immunogenic agent or vaccine comprising same; a target cell transformed or transfected with same; a combination therapeutic comprising same; use of same in treatment of cancer, and a method of treating cancer using same.

The present disclosure relates to methods and compositions for modulating protein expression. In particular, the invention features methods and compositions for increasing protein expression in a cell by delivering to the cell a composition including an mRNA encoding a polypeptide and one or more oligonucleotides, wherein each of the one or more oligonucleotides includes a region of linked nucleotides complimentary to a portion of the sequence of the mRNA. The methods and compositions described herein may be used to modulate gene expression (e.g., increase gene expression), to increase the stability of the mRNA, to decrease the immunogenicity of the mRNA, to enable selective expression (e.g., in a target cell or tissue) of the mRNA, and/or to enable the delivery of two or more mRNAs in a stoichiometric ratio.

The present disclosure relates to methods and compositions for modulating protein expression. In particular, the invention features methods and compositions for increasing protein expression in a cell by delivering to the cell a composition including an mRNA encoding a polypeptide and one or more oligonucleotides, wherein each of the one or more oligonucleotides includes a region of linked nucleotides complimentary to a portion of the sequence of the mRNA. The methods and compositions described herein may be used to modulate gene expression (e.g., increase gene expression), to increase the stability of the mRNA, to decrease the immunogenicity of the mRNA, to enable selective expression (e.g., in a target cell or tissue) of the mRNA, and/or to enable the delivery of two or more mRNAs in a stoichiometric ratio.

The invention relates to antibodies and antigen-binding fragments thereof that recognize coronavirus spike proteins(CoV-S), such asthe spike protein of Middle East respiratory syndrome coronavirusspike protein(MERS-S). In some embodiments, the antibodiesbind to CoV-Swith high affinity, inhibit CoV infection of human cells, inhibit CoV sialic acid-binding activity and/or bind to multiple types of CoV-S. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating CoV infection.

The invention relates to antibodies and antigen-binding fragments thereof that recognize coronavirus spike proteins(CoV-S), such asthe spike protein of Middle East respiratory syndrome coronavirusspike protein(MERS-S). In some embodiments, the antibodiesbind to CoV-Swith high affinity, inhibit CoV infection of human cells, inhibit CoV sialic acid-binding activity and/or bind to multiple types of CoV-S. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating CoV infection.

The present patent application relates to the use of antagonists of delayed rectifier potassium (K.sup.+) channels, more specifically Kv1.3 antagonists, as pharmaceutical agents in the treatment, prevention or reduction of both acute and chronic pain. The results and mode of action disclosed herein describe how Kv1.3 antagonists may act as analgesics through reduction of K.sup.+ currents rather than their potentiation. With regard to their high efficacy in the treatment of pain, these compounds are highly selective for slow delayed rectifier voltage-activated potassium (K.sup.+) currents. Such findings, together with those showing that nitenin, PSORA-4, PAP-1 and AM92016 hydrochloride act as K.sup.+ channel blockers and by their effects on K.sup.+ current inactivation profiles, also translate into an analgesic effect with reduced side effects. The results disclosed herein show that compounds that inhibit delayed rectifying Kv1.3 channels, such as the ones described herein, are a viable alternative to the already existing pharmaceutical compounds used in the treatment of pain, and specially, in chronic pain.

The present patent application relates to the use of antagonists of delayed rectifier potassium (K.sup.+) channels, more specifically Kv1.3 antagonists, as pharmaceutical agents in the treatment, prevention or reduction of both acute and chronic pain. The results and mode of action disclosed herein describe how Kv1.3 antagonists may act as analgesics through reduction of K.sup.+ currents rather than their potentiation. With regard to their high efficacy in the treatment of pain, these compounds are highly selective for slow delayed rectifier voltage-activated potassium (K.sup.+) currents. Such findings, together with those showing that nitenin, PSORA-4, PAP-1 and AM92016 hydrochloride act as K.sup.+ channel blockers and by their effects on K.sup.+ current inactivation profiles, also translate into an analgesic effect with reduced side effects. The results disclosed herein show that compounds that inhibit delayed rectifying Kv1.3 channels, such as the ones described herein, are a viable alternative to the already existing pharmaceutical compounds used in the treatment of pain, and specially, in chronic pain.

The present disclosure provides antibodies that specifically bind to B7-H3. The antibodies find use in a variety of treatment, diagnostic, and monitoring applications, which are also described. The present disclosure provides antibodies that specifically bind to B7-H3. A subject antibody specifically binds B7-H3 from humans and other mammals, e.g., monkey and mouse.

The present disclosure provides antibodies that specifically bind to B7-H3. The antibodies find use in a variety of treatment, diagnostic, and monitoring applications, which are also described. The present disclosure provides antibodies that specifically bind to B7-H3. A subject antibody specifically binds B7-H3 from humans and other mammals, e.g., monkey and mouse.